Recovery from indomethacin-induced gastrointestinal bleeding by treatment with teprenone
Background Gastrointestinal injuries caused by nonsteroidal anti-inflammatory drugs (NSAIDs) is a serious side effect in patients with rheumatoid arthritis (RA). However, effective therapeutic strategies have yet to be established. In this study, we investigated the therapeutic effects of teprenone (TEP), a gastric mucosal protective drug, on NSAID-induced gastrointestinal injuries in rats with RA (AA rats). Methods Gastrointestinal injury was induced by oral administration of indomethacin (IMC), a typical NSAID. TEP was orally administered after IMC-induced gastrointestinal bleeding, and the stomach, jejunum, and ileum were excised. Results On day 14 of IMC administration, lesion areas in the stomach, jejunum, and ileum were significantly larger in AA rats than in normal rats. When TEP was orally administered to AA rats, the lesion areas in the stomach, jejunum, and ileum significantly decreased compared with those in control rats (IMC-induced AA rats). Therefore, we measured NOS2 mRNA and NO levels, which were significantly decreased in rats with IMC-induced AA after treatment with TEP. Conclusions These results suggest that the oral administration of TEP may be useful for the treatment of NSAID-induced gastrointestinal injuries in patients with RA..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:9 |
|---|---|
| Enthalten in: |
Journal of pharmaceutical health care and sciences - 9(2023), 1 vom: 28. Nov. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Deguchi, Saori [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
Gastrointestinal injury |
|---|
| Anmerkungen: |
© The Author(s) 2023 |
|---|
| doi: |
10.1186/s40780-023-00312-y |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR053883497 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR053883497 | ||
| 003 | DE-627 | ||
| 005 | 20231128064702.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231128s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s40780-023-00312-y |2 doi | |
| 035 | |a (DE-627)SPR053883497 | ||
| 035 | |a (SPR)s40780-023-00312-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Deguchi, Saori |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Recovery from indomethacin-induced gastrointestinal bleeding by treatment with teprenone |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2023 | ||
| 520 | |a Background Gastrointestinal injuries caused by nonsteroidal anti-inflammatory drugs (NSAIDs) is a serious side effect in patients with rheumatoid arthritis (RA). However, effective therapeutic strategies have yet to be established. In this study, we investigated the therapeutic effects of teprenone (TEP), a gastric mucosal protective drug, on NSAID-induced gastrointestinal injuries in rats with RA (AA rats). Methods Gastrointestinal injury was induced by oral administration of indomethacin (IMC), a typical NSAID. TEP was orally administered after IMC-induced gastrointestinal bleeding, and the stomach, jejunum, and ileum were excised. Results On day 14 of IMC administration, lesion areas in the stomach, jejunum, and ileum were significantly larger in AA rats than in normal rats. When TEP was orally administered to AA rats, the lesion areas in the stomach, jejunum, and ileum significantly decreased compared with those in control rats (IMC-induced AA rats). Therefore, we measured NOS2 mRNA and NO levels, which were significantly decreased in rats with IMC-induced AA after treatment with TEP. Conclusions These results suggest that the oral administration of TEP may be useful for the treatment of NSAID-induced gastrointestinal injuries in patients with RA. | ||
| 650 | 4 | |a Gastrointestinal injury |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Teprenone |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Indomethacin |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Rheumatoid arthritis |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Nitric oxide |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Iwakami, Ayusa |4 aut | |
| 700 | 1 | |a Tujigiwa, Mizuki |4 aut | |
| 700 | 1 | |a Otake, Hiroko |4 aut | |
| 700 | 1 | |a Mano, Yu |4 aut | |
| 700 | 1 | |a Yamamoto, Naoki |4 aut | |
| 700 | 1 | |a Nakazawa, Yosuke |4 aut | |
| 700 | 1 | |a Misra, Manju |4 aut | |
| 700 | 1 | |a Nagai, Noriaki |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of pharmaceutical health care and sciences |d London : BioMed Central, 2015 |g 9(2023), 1 vom: 28. Nov. |w (DE-627)SPR037742833 |w (DE-600)2809913-8 |x 2055-0294 |7 nnns |
| 773 | 1 | 8 | |g volume:9 |g year:2023 |g number:1 |g day:28 |g month:11 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s40780-023-00312-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 9 |j 2023 |e 1 |b 28 |c 11 | ||